Michael Winlo
Chief Scientific Officer, Emyria
Formerly Emerald Clinics (until September 2020)
1 conversation across 1 show.
Meet the people behind the company.

Latest conversation · What The Health
The Psychedelic Resurgence: From Counterculture to Clinical Breakthrough with Dr Michael WinloEmyria (ASX:EMD) is a Perth-based, ASX-listed biotech developing treatments for mental health and neurological conditions, including psychedelic-assisted therapies for PTSD and treatment-resistant depression. It runs its own clinical service subsidiaries to gather real-world patient data alongside its drug development programmes.
Sources: businessnewsaustralia.com, stockanalysis.com
Chief Scientific Officer, Emyria
Spot something wrong? Suggest a correctionUpdated 29 October 2026
Put your brand alongside the voices founders, investors and operators come to hear.
Explore sponsorshipWe're W2D1 Media — the team behind the Day One Network, and we helped build Blackbird Ventures' Wild Hearts. We turn podcasts into trust, authority and pipeline.